The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Regulatory aspects on nanomedicines
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
Applications of Carbon Nanotubes in Drug Delivery
Kaur, J., Gill, G. S., & Jeet, K. (2019) · Characterization and Biology of Nanomaterials for Drug Delivery · doi:10.1016/b978-0-12-814031-4.00005-2 · Cited by 2,019
Nanotechnology in concrete – A review
Sanchez, F., & Sobolev, K. (2010) · Construction and Building Materials · doi:10.1016/j.conbuildmat.2010.03.014 · Cited by 1,834
Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.009 · Cited by 1,791
The emerging nanomedicine landscape
Wagner, V., Dullaart, A., Bock, A.-K., & Zweck, A. (2006) · Nature Biotechnology · doi:10.1038/nbt1006-1211 · Cited by 1,630
The big picture on nanomedicine: the state of investigational and approved nanomedicine products
Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., & McCullough, J. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2012.05.013 · Cited by 1,088
Biomedical applications of functionalised carbon nanotubes
Bianco, A., Kostarelos, K., Partidos, C. D., & Prato, M. (2005) · Chemical Communications · doi:10.1039/b410943k · Cited by 1,086
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Self-citationThe present and future of nanotechnology in human health care
Sahoo, S. K., Parveen, S., & Panda, J. J. (2007) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2006.11.008 · Cited by 905
Nanomedicines: addressing the scientific and regulatory gap
Tinkle, S., McNeil, S. E., Mühlebach, S., Bawa, R., Borchard, G., Barenholz, Y. (., Tamarkin, L., & Desai, N. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12403 · Cited by 546
Factors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective
Moghimi, S. M., Hunter, A. C., & Andresen, T. L. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134623 · Cited by 545
Dendrimers in Oncology: An Expanding Horizon
Tekade, R. K., Kumar, P. V., & Jain, N. K. (2009) · Chemical Reviews · doi:10.1021/cr068212n · Cited by 466
Characterization of Nanoparticles Intended for Drug Delivery
(2011) · Methods in Molecular Biology · doi:10.1007/978-1-60327-198-1 · Cited by 358
Nanoparticles for Biomedical Imaging: Fundamentals of Clinical Translation
Choi, H. S., & Frangioni, J. V. (2010) · Molecular Imaging · doi:10.2310/7290.2010.00031 · Cited by 351
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines
Dobrovolskaia, M. A., & McNeil, S. E. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.025 · Cited by 309
Gaspar, R., & Duncan, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.06.003 · Cited by 304
Self-citationNanotherapeutics in the EU: an overview on current state and future directions
Pepic, I., Hafner, A., Lovric, J., & Perina Lakos, G. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s55359 · Cited by 294
Etanercept and efalizumab for the treatment of psoriasis: a systematic review
Woolacott, N., Hawkins, N., Mason, A., Kainth, A., Khadjesari, Z., Bravo Vergel, Y., Misso, K., Light, K., Chalmers, R., Sculpher, M., et al. (2006) · Health Technology Assessment · doi:10.3310/hta10460 · Cited by 241
Nanomedicine in Action: An Overview of Cancer Nanomedicine on the Market and in Clinical Trials
Wang, R., Billone, P. S., & Mullett, W. M. (2013) · Journal of Nanomaterials · doi:10.1155/2013/629681 · Cited by 236
Immune system targeting by biodegradable nanoparticles for cancer vaccines
Silva, J. M., Videira, M., Gaspar, R., Préat, V., & Florindo, H. F. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.03.010 · Cited by 233
Self-citationPreparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging
Cai, W., & Chen, X. (2008) · Nature Protocols · doi:10.1038/nprot.2007.478 · Cited by 227
Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking
Conniot, J., Silva, J. M., Fernandes, J. G., Silva, L. C., Gaspar, R., Brocchini, S., Florindo, H. F., & Barata, T. S. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00105 · Cited by 200
Self-citationNanotechnology-based systems for the treatment and prevention of HIV/AIDS
das Neves, J., Amiji, M. M., Bahia, M. F., & Sarmento, B. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.017 · Cited by 197
Nanoparticles for cancer imaging: The good, the bad, and the promise
Chapman, S., Dobrovolskaia, M., Farahani, K., Goodwin, A., Joshi, A., Lee, H., Meade, T., Pomper, M., Ptak, K., Rao, J., et al. (2013) · Nano Today · doi:10.1016/j.nantod.2013.06.001 · Cited by 169
Regulating Nanomedicine – Can the FDA Handle It?
Bawa, R. (2011) · Current Drug Delivery · doi:10.2174/156720111795256156 · Cited by 160
Ehmann, F., Sakai-Kato, K., Duncan, R., Pérez de la Ossa, D. H., Pita, R., Vidal, J.-M., Kohli, A., Tothfalusi, L., Sanh, A., Tinton, S., et al. (2013) · Nanomedicine · doi:10.2217/nnm.13.68 · Cited by 160
Main, C., Bojke, L., Griffin, S. C., Norman, G., Barbieri, M., Mather, L., Stark, D., Palmer, S., & Riemsma, R. P. (2006) · Health Technology Assessment · doi:10.3310/hta10090 · Cited by 156
"Characterization of Nanoparticles Intended for Drug Delivery"
Gabor, F. (2011) · Scientia Pharmaceutica · doi:10.3797/scipharm.br-11-01 · Cited by 142
Applying Nanotechnology to Human Health: Revolution in Biomedical Sciences
Shrivastava, S., & Dash, D. (2009) · Journal of Nanotechnology · doi:10.1155/2009/184702 · Cited by 136
How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider
Schellekens, H., Stegemann, S., Weinstein, V., de Vlieger, J. S. B., Flühmann, B., Mühlebach, S., Gaspar, R. S., Shah, V. P., & Crommelin, D. J. A. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9533-z · Cited by 122
Self-citationModular Nucleic Acid Assembled p/MHC Microarrays for Multiplexed Sorting of Antigen-Specific T Cells
Kwong, G. A., Radu, C. G., Hwang, K., Shu, C. J., Ma, C., Koya, R. C., Comin-Anduix, B., Hadrup, S. R., Bailey, R. C., Witte, O. N., et al. (2009) · Journal of the American Chemical Society · doi:10.1021/ja9006707 · Cited by 89
Videira, M., Arranja, A., Rafael, D. F. D. S., & Gaspar, R. S. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.11.018 · Cited by 61
Self-citationDifferent Pharmaceutical Products Need Similar Terminology
Crommelin, D. J. A., de Vlieger, J. S. B., Weinstein, V., et al. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9532-0 · Cited by 59
Pushed off target with proteins
Gaspar, R. S. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.11 · Cited by 50
Self-citationRuiz, M. E., Gantner, M. E., & Talevi, A. (2013) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574891x113089990038 · Cited by 45
Regulatory Aspects of Oncologicals: Nanosystems Main Challenges
Gaspar, R. S., Florindo, H. F., Silva, L. C., Videira, M., Corvo, M. L., Martins, M. B. F., & Lima, B. S. (2014) · Advances in delivery science and technology · doi:10.1007/978-3-319-08084-0_15 · Cited by 36
Self-citationZhu, J., Zhang, X., Shao, Z., Dai, L., La, L., Hu, X., Wang, X., Zhou, C., & Ao, Y. (2013) · Journal of Nanomaterials · doi:10.1155/2013/831873 · Cited by 35
Dorbeck-Jung, B. R., & Chowdhury, N. (2011) · Law & Policy · doi:10.1111/j.1467-9930.2011.00339.x · Cited by 33
Complement-mediated tumour growth: Implications for cancer nanotechnology and nanomedicines
Moghimi, S. M., & Andresen, T. L. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.02.014 · Cited by 20
Cited by
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
Nanomaterials for cancer therapy: current progress and perspectives
Cheng, Z., Li, M., Dey, R., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01096-0 · Cited by 1,168
Ghezzi, M., Pescina, S., Padula, C., Santi, P., Del Favero, E., Cantù, L., & Nicoli, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.031 · Cited by 1,135
Metadata
- Authors
- Sainz, V., Conniot, J., Matos, A. I., Peres, C., Zupanǒiǒ, E., Moura, L., Silva, L. C., Florindo, H. F., & Gaspar, R. S.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 468
- Issue
- 3
- Pages
- 504-510
- ISSN
- 0006-291X (ISSN-L)
- OpenAlex
- W1088146625
- Cited by
- 417
- References
- 41
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.